Skip to content

The effect of dexmedetomidine on subacute liver function injury after partial hepatectomy in high-altitude areas

The effect of dexmedetomidine on subacute liver function injury after partial hepatectomy in high-altitude areas

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400079922
Enrollment
Unknown
Registered
2024-01-16
Start date
2024-01-20
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

subacute liver function injury after partial hepatectomy in high-altitude areas

Interventions

dexmedetomidine:Intraoperative intravenous administration of dexmedetomidine using a loading dose combined with continuous infusion
Control group:Intravenous administration of 0.9% sodium chloride at the same loading dose and continuous infusion rate

Sponsors

Qinghai Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria (Prior to the study, participants must meet all of the following requirements in order to be enrolled) 1 Age range from 18 to 70 years old, regardless of gender; 2 Permanent population in areas above 2500 meters above sea level; 3 Perform liver resection surgery in our hospital, and use Pringle technique for total hepatic portal block during the operation; 4 American Society of Anesthesiologists (ASA) classification I to III levels; 5 Participants are informed and voluntarily participate, and sign an informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria (prior to the study, subjects are not eligible for enrollment if they meet any of the following requirements): 1. Patients with severe heart, lung, brain, kidney and other important organ diseases; Patients with pulmonary dysfunction (PaO2<60mmHg) or concomitant chronic obstructive pulmonary disease; Patients with chronic diseases such as hypertension and diabetes; Patients with concomitant neurological and psychiatric disorders; Patients who have experienced severe myocardial infarction within the past three months; Rupture or bleeding of liver tumors; Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
liver function;

Secondary

MeasureTime frame
Renal function;blood routine examination;Blood coagulation function;inflammatory factor;Hemodynamic indicators;

Countries

China

Contacts

Public ContactWang Hongxia

Qinghai Provincial People's Hospital

448290102@qq.com+86 139 9722 2705

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026